Performance of biopharma companies therapeutic focus vs diversified 2020
As of late 2020, the five-year average return on invested capital was estimated to be 12.5 percent for biopharmaceutical companies with greater therapeutic focus, while companies with greater diversification saw only a four percent increase in the same time period. This statistic illustrates the performance of biopharmaceutical companies with greater therapeutic focus compared to more diversified peers, by selected metrics.
